The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Open accessThe DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. The IL-23/IL-17 axis is an important pathway for targeted therapy for inflammatory diseases. Emerging evidence from clinical trials has shown that monoclonal antibodies against IL-23, IL-17, and tumor necrosis factor are effective in the treatment of patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Here, we summarize the latest knowledge about the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis in inflammatory skin diseases. The currently available biologics targeting the axis is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265 · cited 1×
“The T helper 17 (Th17) cells constitute a unique subset of CD4 T cells and are the major source of IL-17 (5).”
BackgroundIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 4×
“In general, IL-23 is involved in the activation of Th17 cells to induce the production of IL17A, IL-17F, tumor necrosis factor (TNF), and IL-6 (20).”
BackgroundInfluentialSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 13×
“Moreover, the data from an open-label study have indicated significant beneficial effect of brodalumab on psoriatic erythroderma (n = 18) and generalized pustular psoriasis (n = 12; Supplementary Table) (93).”
MethodInfluentialPlasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910 · cited 1×
“In psoriasis, the combination of LL37 with the patient’s own DNA leads to the activation of the Toll-like receptor 9 (54).”
BackgroundLeonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationInterleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Increased expression of interleukin 17 in inflammatory bowel disease
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., & Fujiyama, Y. (2003) · Gut · doi:10.1136/gut.52.1.65 · Cited by 1,713
Innate IL-17-producing cells: the sentinels of the immune system
Cua, D. J., & Tato, C. M. (2010) · Nature Reviews Immunology · doi:10.1038/nri2800 · Cited by 1,578
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Self-citationChronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Cited by
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
“It is a key regulator of the type 17 pathway activating a variety of cells, including T H 17, Tc17, γδ T cells, and innate lymphoid cells type 3 (ILC3) to produce IL-17 [108].”
BackgroundJAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
The Role of Helper T Cells in Psoriasis
Hu, P., Wang, M., Gao, H., Zheng, A., Li, J., Mu, D., & Tong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788940 · Cited by 214
New and Emerging Targeted Therapies for Hidradenitis Suppurativa
Markota Čagalj, A., Marinović, B., & Bukvić Mokos, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073753 · Cited by 74
Treatment Advances in Vitiligo: An Updated Review
Binti Ismail, I., Jabeen Bhat, Y., & Shurjeel ul Islam, M. (2025) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1501a4600 · Cited by 15
“This paradox may be explained by the multifactorial pathophysiology of vitiligo, which includes upregulation of ICAM-1 molecules on melanocytes and other cytokines like IFN γ , which attract more cytotoxic T cells to the lesional skin [53].”
Cytokine-Mediated Molecular Pathophysiology of Hidradenitis Suppurativa: A Narrative Review
Melchor, J., Prajapati, S., Pichardo, R. O., & Feldman, S. R. (2024) · Skin Appendage Disorders · doi:10.1159/000536268 · Cited by 13
“Interleukin-23 (IL-23) is a heterodimeric cytokine that stimulates CD4+ helper T cells (Th17 cells) to produce the proin fl ammatory cytokine IL-17 and thus the in-fl ammatory cascade [8, 18].”
BackgroundMethodInfluentialAndrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“Interleukin-23, acting through the IL-23R receptor—whose expression is upregulated upon activation of Th17 lymphocytes—initiates a signalling pathway involving the transcription factor STAT3 and stabilises the expression of the transcription factor ROR-γ t [63].”
Off-label dermatologic uses of IL-23 inhibitors
Porter, J., Zimmerman, L., Nickles, M., & Hoyer, S. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2436015 · Cited by 3
Metadata
- Authors
- Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-11-17
- Volume
- 11
- Pages
- 594735-594735
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3100055007
- Cited by
- 386
- References
- 149
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.